Comparative Pharmacology
Head-to-head clinical analysis: EMEND versus TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMEND versus TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE.
EMEND vs TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective substance P/neurokinin 1 (NK1) receptor antagonist, which inhibits the binding of substance P in the emetic pathway.
Trimethobenzamide is a centrally acting antiemetic that inhibits the chemoreceptor trigger zone (CTZ) in the medulla oblongata by suppressing emetic stimuli. Its exact mechanism is not fully understood but may involve antagonism of dopamine D2 receptors and possibly serotonin 5-HT3 receptors.
125 mg orally once 1 hour before chemotherapy; then 80 mg orally once daily on Days 2 and 3.
300 mg orally or intramuscularly 3 to 4 times daily as needed for nausea and vomiting.
None Documented
None Documented
9–13 hours (terminal) in healthy adults; clinically, this supports once-daily dosing. In patients with severe renal impairment (CrCl <30 mL/min), half-life is prolonged to ~16 hours.
Terminal elimination half-life approximately 7-9 hours in adults; prolonged in renal impairment (up to 20-30 hours).
Primarily metabolized; ~5% unchanged in urine, ~57% in feces as metabolites, ~32% in urine as metabolites. Renal elimination of parent drug is minimal.
Primarily renal (50-70% as unchanged drug and metabolites) and biliary (~20-30%); less than 5% fecal.
Category C
Category C
Antiemetic
Antiemetic